AI-written plain-language discharge summaries for people with blood and other cancers
Official title: Prospective Randomized Controlled Trial to Evaluate Locally Implemented Large Language Models (LLMs) for Simplifying Patient Communication in Hematology and Oncology
Run by Technical University of Munich · NCT07519811 · Data updated 2026-11-12
This project tests whether AI-written plain-language discharge letters help adults with hematologic or other cancers understand their diagnosis, treatment, and next steps better than the usual medical letter.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Technical University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | April 1, 2027 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT07519811 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult inpatients of the Department of Medicine III (Hematology/Oncology) at Klinikum rechts der Isar who receive a routine discharge letter containing the specified sections and are able to give informed consent.
✕Probably not a fit
Patients with significant cognitive impairment, those whose discharge letters lack the targeted sections, or people unable to read the simplified language may not gain benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, prospective randomized controlled trial at the Technical University of Munich randomizes hematology and oncology inpatients 2:1 to receive an AI-simplified discharge letter plus the standard letter or the standard letter alone. An on-premise large language model automatically simplifies key sections of the discharge letter and a study physician reviews and approves the simplified text before patient delivery. Patients with limited German proficiency are enrolled in a separate, nonrandomized translation arm where letters are simplified and translated. The primary outcome is a 5-item Likert-based comprehension score with questionnaires completed after patients read their letters.
Why it matters
Potential benefit: If successful, patients could better understand their care plans and follow-up instructions, which may improve adherence and reduce post-discharge confusion.
How similar studies have gone: Prior technical and observational work shows LLMs can produce accurate plain-language medical summaries, but randomized trials testing clinical benefit in oncology discharge care are lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Inpatient of the Department of Medicine III (Hematology/Oncology) at TUM University Hospital (Klinikum rechts der Isar), Munich, Germany * Receipt of a discharge letter including the sections Current Status, Medical History, Epicrisis, and Further Management as part of routine clinical care * Capacity to provide informed consent * Written informed consent following the consent procedure Exclusion Criteria: * Cognitive impairment precluding independent assessment of comprehension (e.g., dementia, severe encephalopathy) * Participation in another study with potential influence on the study endpoints * Lack of capacity to provide informed consent * Refusal to participate in the study
Where it's running
-
Technical University Munich
Munich, Bavaria, Germany Recruiting
Study contacts
- Study coordinator: Krischan Braitsch, MD
- Email: krischan.braitsch@tum.de
- Phone: +49 089 4140 1268
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant
This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.
-
KK2430 in people with hematologic cancers
This study tests KK2430 in adults with blood-related cancers to see if it is safe and how it behaves in the body, with the goal of understanding its potential to help in treatment.
-
JNJ-95804306 in relapsed or refractory blood cancers
This study tests JNJ-95804306 in people with relapsed or refractory hematologic cancers to find a safe dose and see if it helps control the disease when given alone or with standard therapy.
-
Flu vaccine strategies for adults with blood cancers
This study will test three different flu vaccines to see which gives the strongest antibody and T-cell responses in adults with blood cancers, including people after autologous stem cell transplant or CAR-T therapy.
-
Combining donor-derived anti-CD19 CAR-T cells with haploidentical transplant using post-transplant cyclophosphamide
This trial tests whether giving donor-derived anti-CD19 CAR-T cells together with a haploidentical bone marrow transplant using post-transplant cyclophosphamide can help adults (18–75) with high‑risk CD19+ blood cancers.
-
Using a new imaging technique to detect cancer-associated fibroblasts in various cancers
This study is testing a new imaging method to see if it can better detect certain cancer-related cells in people with newly diagnosed esophageal or pancreatic cancer compared to standard imaging techniques.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.